Advancements in the treatment of psoriasis: role of biologic agents.

Journal of managed care pharmacy : JMCP

Volumn 10, Issue 4, 2004, Pages 318-325

  Rich, Sheldon J ^a   Bello Quintero, Christina E ^a  

^a Associates LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; BIOLOGICAL PRODUCT; DERMATOLOGICAL AGENT; EFALIZUMAB; HYBRID PROTEIN; IMMUNOGLOBULIN G; INFLIXIMAB; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; ECONOMICS; HUMAN; IMMUNOLOGY; PSORIASIS; PUVA; RANDOMIZED CONTROLLED TRIAL; REVIEW; ULTRAVIOLET RADIATION;

ANTIBODIES, MONOCLONAL; BIOLOGICAL PRODUCTS; COST-BENEFIT ANALYSIS; DERMATOLOGIC AGENTS; HUMANS; IMMUNOGLOBULIN G; PSORIASIS; PUVA THERAPY; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; ULTRAVIOLET RAYS;

EID: 5144231873     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2004.10.4.318     Document Type: Review

References (43)